QT Prolongation in Critically Ill Patients With SARS-CoV-2 Infection

Wasim S. El Nekidy, PharmD, Khalid Almuti, MD, Hazem ElRefaei, PharmD, Bassam Atallah, PharmD, Lana M. Mohammad, RPh, Wael AlMahmeed, MD, Mohamed Badr, MD, Khaled Abdallah, MD, Fadi Hamed, MD, and Jihad Mallat, MD

Abstract

Background: Several reports linked the use of repurposed drugs such as hydroxychloroquine (HCQ), azithromycin, lopinavir/ritonavir, and favipiravir with QT interval prolongation in patients with SARS-CoV-2 infection. Little is known about the risk factors for QT interval prolongation in this population. We sought to describe the prevalence and identify the main risk factors associated with clinically significant corrected QT (QTc) prolongation in this population. Methods: We conducted a retrospective analysis of critically ill patients who were admitted to our intensive care unit (ICU), had at least one electrocardiogram performed during their ICU stay, and tested positive for SARS-CoV-2. Clinically significant QTc interval prolongation was defined as QTc >500 milliseconds (ms). Results: Out of the 111 critically ill patients with SARS-CoV-2 infection, QTc was significantly prolonged in 47 cases (42.3%). Patients with a clinically significant QTc prolongation had significantly higher proportions of history of cardiac diseases/surgery (22 [46.8%] vs. 10 [15.6%], \(P < .001\)), hypokalemia (10 [21.3%] vs. 5 [7.8%], \(P = .04\)), and male gender (95% vs. 82.8%, \(P = .036\)) than patients with QTc ≤500 ms, respectively. A total of 46 patients (41.4%) received HCQ, 28 (25.2%) received lopinavir/ritonavir, and 5 (4.5%) received azithromycin. Multivariate logistic regression analysis showed that a history of cardiac disease was the only independent factor associated with clinically significant QTc prolongation (\(P = .004\) for the likelihood-ratio test). Conclusion: The prevalence of clinically significant QTc prolongation in critically ill patients with SARS-CoV-2 infection was high and independent of drugs used. Larger prospective observational studies are warranted to elucidate independent risk factors associated with clinically significant QTc prolongation in this study population.

Keywords

QTc, prolongation, critically ill, COVID-19, SARS-CoV-2

Introduction

The SARS-CoV-2 pandemic has significantly impacted many countries around with an influx of critically ill patients secondary to acute respiratory distress syndrome.\(^1\) Data has shown that elderly patients and those with underlying comorbid conditions such as diabetes mellitus, hypertension, and cardiovascular disease are more prone to develop severe SARS-CoV-2 infection.\(^1\) Several studies have linked the use of certain repurposed drugs such as hydroxychloroquine (HCQ), azithromycin, lopinavir/ritonavir, and favipiravir with QT interval prolongation in this population.\(^5\) QT interval prolongation is a disorder of myocardial repolarization identified by a prolonged QT interval on the electrocardiogram (ECG). This syndrome is associated with an increased risk of the polymorphic ventricular tachycardia torsades de pointes (TdP) which is a life-threatening condition.\(^6,11\) QT interval prolongation is also associated with palpitations, syncope, seizures, and sudden cardiac death. These clinical manifestations may be difficult to detect in critically ill patients.

\(^1\) Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
\(^2\) Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA
\(^3\) Gulf Medical University, Ajman, United Arab Emirates
\(^4\) West Hertfordshire NHS Trust, Watford, United Kingdom
\(^5\) Cambridge University Hospitals, Cambridge, United Kingdom
\(^6\) Normandy University, Caen, France

Manuscript submitted: August 08, 2021; accepted: December 09, 2021.

Corresponding Author:
Wasim S. El Nekidy, Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, P.O. Box 112412, Abu Dhabi, United Arab Emirates.
Email: elnekiw@clevelandclinicabudhabi.ae

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Corrected QT (QTc) prolongation can be either congenital or acquired. Congenital long QT syndrome is an inherited cardiac condition with a predisposition for abnormal myocardial repolarization.\(^{11,13}\) Conversely, acquired QT prolongation usually results from drug therapy. Electrolyte derangements, including hypokalemia, hypomagnesemia, and hypocalcemia. Also, bradycardia can increase the risk of drug-induced QT interval prolongation. Other risk factors such as impaired kidney and/or liver function, underlying heart failure, myocardial infarction, left ventricular hypertrophy, and advanced age can also contribute.\(^{11,13}\) Several pharmacologic agents are associated with QT interval prolongation such as fluorquinolones, macrolides, hydroxychloroquine, favipiravir, and azole antifungals in addition to antiemetics such as metoclopramide and ondansetron. Many of these agents carry the United States FDA boxed warnings for QTc prolongation and require close monitoring when used.\(^{11,13}\)

Experts suggest that QTc values of >450 milliseconds (ms) in adult males, and >460 ms in adult females are considered prolonged.\(^{11-15}\) Clinically significant QTc interval prolongation >500 ms increases the risk of life-threatening arrhythmias.\(^{11-15}\) We observed several critically ill patients with SARS-CoV-2 infection with significant QTc prolongation. The primary objective was to describe the prevalence of clinically significant QTc interval prolongation in critically ill patients with the SARS-CoV-2 infection. The secondary objective of the study was to identify the independent risk factors associated with clinically significant QTc interval prolongation in these patients.

**Methods**

This was a retrospective observational study conducted at our quaternary care hospital between March 1, 2020, and June 30, 2020. Data collection began after approval from the Research Ethics Committee. Patient demographics and baseline characteristics were collected. Pertinent data on use of medications potentially associated with QTc prolongation was collected. Our primary objective was to examine the prevalence of clinically significant QTc prolongation in patients with a positive SARS-CoV-2 infection. Our secondary objective was to identify the independent risk factors associated with clinically significant QTc prolongation in these patients.

**Patient Selection**

Patients were included if they were adults (≥18 years of age), admitted to our intensive care unit (ICU) and tested positive for SARS-CoV-2 by the polymerase chain reaction method to detect the virus using a nasopharyngeal swab. Each patient had at least one ECG performed during the hospital admission. The longest QTc ECG measurement during each patient’s hospital admission was included in the analysis. All associated laboratory findings (either on the same day of ECG or within 24 hours prior to the ECG reading) and all potential drugs (prior to the ECG reading) were included in this analysis. Due to the prolonged half-life of HCQ (40 days), we included patients who received this medication at any time during the same admission prior to the QTc measurement. All data were collected from the electronic medical records system.

**Definitions of Variables**

QTc prolongation was defined as ECG with QTc >450/460 ms in males and females, respectively. Additionally, our primary analysis was conducted for patients who had clinically significant QTc prolongation defined as QTc >500 ms. All computer-generated QT readings were further measured manually by a cardiac electrophysiologist who calculated QTc intervals using the Bazett’s formula.\(^{16}\) In case of any significant discrepancy in the measurements, the physician reading was used for analysis. There was a substantial agreement between the cardiac electrophysiologist reading and the machine reading (kappa-statistic: 0.69 ± 0.09, \(P < .001\)). To qualify as having “other cardiac history,” patients had to have a history of ischemic heart disease (coronary artery disease, myocardial infarction) or cardiac surgery (valve replacement or coronary artery bypass surgery). Other drugs that may have been administered during their hospital course and that were included in the list of those potentially contributing to prolonged QTc intervals were haloperidol, olanzapine, ondansetron, quetiapine, metoclopramide, or fluoroquinolones. Acute liver injury was determined when liver enzymes increased to more than 3 times the baseline. Acute kidney injury was determined based on the nephrologist documented diagnosis.

**Data Analysis**

Normality of data distribution was assessed using the Shapiro-Wilk test and by visual inspection of each variable’s distribution (histogram). Data are expressed as mean ± SD when normally distributed or median (IQR) when non-normally distributed. Proportions were used as descriptive statistics for categorical variables. Comparisons of values between independent groups were performed by the two-tailed Student’s \(t\) test or the Mann-Whitney \(U\) test, as appropriate. Analysis of the discrete data was performed by Chi-Square (\(\chi^2\)) test or Fisher’s exact test when the numbers were small.

Independent risk factors of clinically significant QTc prolongation were assessed using multivariable logistic regression analysis. All variables with a \(P\)-value <.1 in the univariate analysis or which were known to influence QTc intervals were included in the multivariable logistic regression model to identify the independent factors of clinically significant QTc prolongation. The potential problem of co-linearity was evaluated using the Spearman’s rank- or Pearson correlation coefficient before running the analysis. Goodness-of-fit was assessed using the Hosmer-Lemeshow test.

A two-side \(P\)-value <.05 was used as the criteria to determine statistical significance in this study. All statistical
analyses were performed using SPSS statistical package version 27 for Microsoft Windows (IBM, Armonk, New York).

**Results**

From March 1 to May 29, 2020, 111 adult patients who were admitted to the ICU with acute respiratory failure caused by SARS-CoV-2 infection and had an ECG performed during the study period were included in the analysis. The QTc interval was prolonged in 86 patients (77.5%) with QTc >450/460 (males/females, respectively). Clinically significant QTc prolongation (QTc > 500 ms) was observed in 47 patients (42.3%).

Table 1 represents the demographics and baseline characteristics of patients with clinically significant QTc prolongation compared to those with no significant QTc prolongation. Patients with clinically significant QTc prolongation had higher rates of cardiac history (22 [46.8%] vs. 10 [15.6%], P <.001), and hypokalemia defined as K⁺ <3.5 mmol/L (10 [21.3%] vs. 5 [7.8%], P = .04) compared to those with QTc ≤500 ms. Furthermore, male gender was significantly more frequent in patients who had clinically significant QTc prolongation than patients with QTc ≤500 ms (95% vs. 82.8%, P = .036). Of the 47 patients with significantly prolonged QTc, 8 (17%) were on continuous renal replacement therapy, and 2 (4.2%) were on intermittent hemodialysis at the time of QTc prolongation.

In the multivariable logistic regression analysis after including heart rate, sex, body mass index, age, comorbidities (including any cardiac disease), renal function, and electrolytes, only a history of cardiac disease was the only risk factor independently associated with clinically significant QTc prolongation (Table 2).

Additional analyses were performed on patients who had QTc prolongation >450/460 ms (Table 1S, supplementary file). No risk factors were found to be independently associated with prolonged QTc (>450/460 ms) in the multivariable logistic regression analysis (Table 2S, supplementary file).

**Discussion**

Our study’s findings demonstrated a relatively high prevalence (42.3%) of clinically significant QTc interval prolongation in our sample population. A history of cardiac disease was the sole risk factor that was independently associated with clinically significant prolonged QTc intervals.

More than 200 medications are known to cause QTc prolongation. The incidence of QTc prolongation in critically ill patients can reach 0.07% over 2 months period. Moreover, the incidence of cardiac arrest caused by TdP can reach up to 6%. Hydroxychloroquine and azithromycin were widely used following the onset of the pandemic to treat patients with the SARS-CoV-2 infection. These medications are known to prolong the QTc interval and have been associated with TdP. The incidence of QTc interval prolongation associated with HCQ use was reported as approximately 10% with an increase following the addition of azithromycin to the treatment regimen. Similarly, lopinavir/ritonavir and favipiravir were reported to prolong the QTc interval when combined with HCQ. A retrospective cohort study of 90 patients with the SARS-CoV-2 infection who received HCQ for at least one day, or HCQ with azithromycin, demonstrated significant QTc interval prolongation compared to baseline (19% of patients receiving HCQ and 21% of patients receiving HCQ and azithromycin). Similarly, Chorin et al retrospectively followed the ECG measurements of 251 patients diagnosed with SARS-CoV-2 infection and treated with HCQ and azithromycin and observed clinically significant QTc prolongation >500 ms in 23% of the patients. Additionally, previous separate studies have corroborated the association of the medication combination of HCQ and azithromycin with QTc interval prolongation. Further, Russo et al retrospectively investigated the effect of the triple combination of HCQ, azithromycin, and lopinavir/ritonavir on QTc interval prolongation in 87 patients infected with SARS-CoV-2 infection. The authors found that 23% of patients showed clinically significant QTc prolongation and concluded that close monitoring of patients receiving those medications is necessary. Additionally, Çap et al retrospectively compared the QTc intervals in 189 patients with the SARS-CoV-2 infection who received HCQ, HCQ plus favipiravir, or favipiravir alone. The authors found that HCQ, but not favipiravir, was independently associated with QTc interval duration in the multivariable linear regression analysis. Finally, Changal and colleagues, in a retrospective observational study, observed QT interval prolongation in 69 out of 279 hospitalized patients with SARS-CoV-2 infection. The authors determined that underlying cardiovascular disease, elderly, CKD, and drugs such as hydroxychloroquine/azithromycin could have been associated with QT prolongation.

Our study demonstrated a higher rate of clinically significant QTc prolongation in our sample compared to previous studies. The discrepancy may be explained by differences in the populations studied. Indeed, we focused on patients with life-threatening SARS-CoV-2 disease with acute respiratory failure requiring ICU admission while previous reports included patients with less severe manifestations. We did not find an independent association between the different medications (HCQ, favipiravir, azithromycin, and lopinavir/ritonavir) and clinically significant QTc prolongation in our population. It is noteworthy that, unlike our analyses, the investigators of the aforementioned studies did not compare patients with QTc prolongation with those who did not to ascertain whether the interval prolongation was associated with medication administration or the underlying disease state.

Several risk factors may contribute to QTc prolongation such as female sex; advanced age; acute myocardial infarction; electrolytes imbalance; heart failure; concomitant administration of QTc prolonging medications; and inadequate drug dose adjustments in patients with compromised renal or hepatic function. Additionally, genetic predisposition comprises around 30% of patients who develop drug-induced QTc prolongation. Our findings showed no association of any of
Table 1. Comparisons of Demographics and Baseline Characteristics Between QTc \(<500\) ms and QTc \(\geq500\) ms Groups.\(^a\)

| Variable                                               | All patients (n = 111) | QTc < 500 ms (n = 64) | QTc \(\geq500\) ms (n = 47) | P value |
|--------------------------------------------------------|------------------------|-----------------------|-----------------------------|---------|
| QT on ECG sheet, ms                                    | 398 (362-456)          | 383 (355-397)         | 477 (416-520)               | <.001   |
| QT calculated by EP, ms                               | 390 (360-453)          | 369 (354-400)         | 482 (443-527)               | <.001   |
| HR on ECG, beat/minute                                 | 90 ± 20                | 93 ± 18               | 87 ± 23                     | .134    |
| HR by EP, beat/minute                                  | 90 ± 20                | 93 ± 18               | 87 ± 23                     | .132    |
| Males, n (%)                                           | 98 (88.3)              | 53 (82.8)             | 45 (95.7)                   | .036    |
| BMI, kg/m\(^2\)                                        | 26.8 (23.9-30.9)       | 28.3 (23.7-30.5)      | 25.3 (23.4-32.3)            | .288    |
| Age, years                                             | 49 (40-59)             | 49 (40.5-61.5)        | 52 (38.8-61.8)              | .168    |
| Hypertension, n (%)                                    | 54 (48.6)              | 28 (43.8)             | 26 (55.3)                   | .228    |
| Diabetes, n (%)                                         | 47 (42.3)              | 25 (39.1)             | 22 (46.8)                   | .414    |
| Cardiac history (any), n (%)                           | 32 (28.8)              | 10 (15.6)             | 22 (46.8)                   | <.001   |
| CHF, n (%)                                              | 9 (8.1)                | 1 (1.6)               | 8 (17)                      | .004    |
| Cardiac arrhythmia, n (%)                              | 7 (6.3)                | 5 (7.8)               | 2 (4.3)                     | .697    |
| Other cardiac history, n (%)                           | 24 (21.6)              | 6 (9.4)               | 18 (38.3)                   | <.001   |
| Invasive mechanical ventilation, n (%)                 | 67 (60.4)              | 34 (63.1)             | 33 (70.2)                   | .069    |
| Renal function, n (%)                                  |                        |                       |                             | .068    |
| Normal                                                 | 66 (59.5)              | 43 (67.2)             | 23 (48.9)                   |         |
| AKI/CKD                                                | 30 (27)                | 16 (25)               | 14 (29.8)                   | .134    |
| RRT                                                    | 15 (13.5)              | 5 (7.8)               | 10 (21.3)                   |         |
| Liver function, n (%)                                  |                        |                       |                             | .537    |
| Normal                                                 | 64 (57.7)              | 35 (54.7)             | 29 (61.7)                   |         |
| Elevated (<3 times baseline)                           | 39 (35.1)              | 23 (35.9)             | 16 (34)                     |         |
| Acute failure (>3 times baseline)                      | 8 (7.2)                | 6 (9.4)               | 2 (4.3)                     |         |
| Magnesium (mmol/L)                                     | 0.92 (0.85-1.01)       | 0.9 (0.8-1.03)        | 0.95 (0.89-1.02)            | .344    |
| (n = 97)                                               | N = 53                 | N = 44                |                             |         |
| Magnesium level n (%)                                  |                        |                       |                             | 1       |
| Normal level (0.65-1.05)                               | 83 (85.6)              | 45 (84.9)             | 38 (86.4)                   | .04     |
| Hypermagnesemia                                        | 14 (14.4)              | 8 (15.1)              | 6 (13.6)                    |         |
| Potassium level (mmol/L)                               | 4 (3.6-4.3)            | 3.95 (3.7-4.3)        | 4 (3.6-4.2)                 | .526    |
| Potassium level n (%)                                  | 96 (86.5)              | 59 (92.2)             | 37 (78.7)                   | .04     |
| Normal level (3.5-5)                                   | 15 (13.5)              | 5 (7.8)               | 10 (21.3)                   |         |
| Hypokalemia                                            | 20.9 ± 0.17            | 20.9 ± 0.16           | 20.7 ± 0.17                 | .451    |
| Calcium mmol/L (n = 106)                               | 2.24 (2.17-2.32)       | 2.22 (2.13-2.29)      | 2.25 (1.99-2.37)            | .368    |
| Corrected calcium (mmol/L)                             | (n = 70)               | N = 36                | N = 34                      | .772    |
| Ionized calcium (mmol/L)                               | 1.15 (1.11-1.19)       | 1.15 (1.12-1.19)      | 1.15 (1.11-1.2)             |         |
| (n = 96)                                               | N = 55                 | N = 41                |                             |         |
| Inflammatory markers elevated (yes), n (%) (CRP, IL6, or ferritin) | 110 (99.1)             | 63 (98.4)             | 47 (100)                    | 1       |
| Mortality                                              | 27 (24.3)              | 13 (20.3)             | 14 (29.8)                   | .25     |
| Favipiravir                                             | 25 (22.5)              | 12 (18.8)             | 13 (27.7)                   | .267    |
| Hydroxychloroquine                                     | 46 (41.4)              | 23 (35.9)             | 23 (49.9)                   | .17     |
| Lopinavir/Ritonavir                                     | 28 (25.2)              | 14 (21.9)             | 14 (29.8)                   | .343    |
| Azithromycin                                           | 5 (4.5)                | 3 (4.7)               | 2 (4.3)                     | 1       |
| Other drug known to prolong QT interval\(^b\)          | 27 (24.3)              | 17 (26.6)             | 10 (21.3)                   | .521    |
| Combination favipiravir and hydroxychloroquine         | 20 (18.0)              | 10 (15.6)             | 10 (21.3)                   | .44     |
| Combination favipiravir and lopinavir/ritonavir        | 12 (10.8)              | 4 (6.2)               | 8 (17.0)                    | .12     |
| Combination lopinavir/ritonavir and hydroxychloroquine | 22 (19.8)              | 11 (17.2)             | 11 (23.4)                   | .42     |
| Combination hydroxychloroquine and azithromycin        | 2 (1.8)                | 1 (1.6)               | 1 (2.1)                     | 1.00    |
| Combination favipiravir and hydroxychloroquine and lopinavir/ritonavir | 8 (7.2)                | 3 (4.7)               | 5 (10.6)                    | .28     |

Abbreviations: AKI, acute kidney injury; BMI, body mass index; CHF, congestive heart failure; CKD, chronic kidney disease; ECG, electrocardiogram; EP, electrophysiologist; HR, heart rate; ms, milliseconds; RRT, renal replacement therapies (IHD and CVVH).

\(^a\) Data are shown as mean ± SD, median (1st-3rd), and count (%). P ≤ .05 was considered statistically significant. Mann-Whitney test was used to compare medians (1st-3rd) between the two QTc groups. Student t test was used to compare means ± SD between the two QTc groups. Chi-square or Fisher exact test was used to compare proportions between the two QTc groups. The general null hypothesis was equality of variables distribution between the two QTc groups.

\(^b\) Quetiapine, haloperidol, fluoroquinolones, ondansetron, amiodarone, or metoclopramide.
the previously mentioned factors with clinically significant QTc prolongation (Table 2) with the exception of a history of cardiac disease. This suggests a possible correlation between direct effects of the SARS-CoV-2 virus and QTc interval prolongation in patients with underlying cardiac disease. This suggestion is in compliance with the findings of Brauninger and colleagues where the investigators advocated that the viral infection can destruct the cardiomyocytes. Future studies are warranted to investigate a potential pathophysiological mechanism of QTc interval prolongation in patients infected by SARS-CoV-2.

Our study has some limitations. This was a single-center retrospective study at a quaternary care facility in the Middle East region. Also, the majority of our patients was male (88.3%). This might be explained by the high proportion of male in the UAE population, which is around 72%. Thus, our findings may not be generalizable to other facilities and populations. Despite multivariable analysis, we cannot rule out selection bias. Our analysis did not include the occurrence of any documented cardiac arrhythmias in those who had significantly prolonged QTc. However, the in-hospital mortality did not differ between patients who had clinically significant QTc prolongation and those who did not. Also, we can be sure that symptomatic arrhythmias did not occur as these arrhythmias would have been documented and would not have been missed. There was a lack in information regarding patient’s genetic history with respect to congenital long QT syndrome in our sample. Finally, we do not have the pre-SARS-CoV-2 incidence of QTc prolongation at our institution.

Conclusion
Critically ill patients with SARS-CoV-2 infection can exhibit high prevalence of clinically significant QTc prolongation irrespective of medications used. QTc prolongation in this population should be closely monitored. Larger prospective observational studies are required to find the independent factors associated with QTc prolongation in this population and also in vaccinated individuals.

Authors’ Note
This work was approved by the institutional Research Ethics Committee.

Author Contributions
All authors have contributed significantly to all parts of this paper and all authors agree with the content of the manuscript. Authors WE, KL, HE, BA, WA, FH, KA, MB, and JM contributed to design; authors WE, LM, BA, and HE contributed to data collection; authors WE and JM contributed to the data analysis. All authors contributed to writing, interpretation, and reviewing the final manuscript. All authors contributed to the writing of the final manuscript. All members of the team contributed to the management or administration of the trial. All authors contributed significantly to the research.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Wasim S. El Nekidy https://orcid.org/0000-0003-3109-0590

Supplemental Material
Supplemental material for this article is available online.

References
1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5. PMID: 31986264; PMCID: PMC7159299. Erratum in: Lancet. Jan 30, 2020
2. Abdallah K, Hamed F, Rahman N, Salam S, Mallat J. Characteristics of critically ill patients infected with COVID-19 in Abu Dhabi, United Arab Emirates. Anaesth Crit Care Pain Med. 2020;39(4):483-485. doi:10.1016/j.accpm.2020.06.014. PMID: 32660852; PMCID: PMC7328597.
3. Atallah B, Sadik ZG, Salem N, et al. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients. Anaesthesia. 2021;76(3):327-335. doi:10.1111/anae.15300. PMID: 33047335; PMCID: PMC7675553.
4. Salem N, Atallah B, El Nekidy WS, Sadik ZG, Park WM, Mallat J. Thromboelastography findings in critically ill COVID-19 patients. J Thromb Thrombolysis. 2021;51(4):961-965. doi:10.1007/s11239-020-02300-7. PMID: 33011896; PMCID: PMC7532945.
5. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA

Table 2. Multivariate Logistic Regression Analysis (QTc > 500 ms).a

| Variable                  | OR (CI)   | P value |
|---------------------------|-----------|---------|
| Heart rate                | .990 (.965-1.014) | .404    |
| Sex                       | .213 (0.029-1.571) | .129    |
| BMI                       | 1.005 (0.923-1.094) | .911    |
| Age                       | 1.018 (0.980-1.058) | .357    |
| Hypertension              | 0.989 (0.336-2.912) | .948    |
| Diabetes                  | 0.875 (0.31-2.473) | .802    |
| Cardiac disease           | 5.054 (1.583-16.139) | .006    |
| Mechanical ventilation    | 1.438 (0.468-4.423) | .526    |
| Kidney function           | 1.343 (0.66-3.876) | .585    |
| Magnesium level           | 0.9 (0.25-32.751) | .954    |
| Potassium level           | 0.77 (0.281-2.11) | .612    |
| Ionized Ca level          | 0.566 (0.032-10.016) | .698    |
| Medications (all medications) | 1.033 (0.362-2.944) | .952    |

a The Hosmer-Lemeshow test P value = .187.
6. Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020;17(9):1425-1433. doi:10.1016/j.hrthm.2020.05.014. PMID: 32485061; PMCID: PMC7429030.

7. Maraj I, Hummel JP, Taoutel R, et al. Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin. J Cardiovasc Electrophysiol. 2020;31(8):1904-1907. doi:10.1111/jce.14594. PMID: 32485061; PMCID: PMC7300464.

8. Ramireddy A, Chugh H, Reinier K, et al. Experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic: implications for QT interval monitoring. J Am Heart Assoc. 2020;9(12):e017144. doi:10.1161/JAHA.120.017144. PMID: 32463348; PMCID: PMC7429030.

9. Russo V, Carbone A, Mottola FF, et al. Effect of triple combination therapy with lopinavir-ritonavir, azithromycin, and hydroxychloroquine on QT interval and arrhythmic risk in hospitalized COVID-19 patients. Front Pharmacol. 2020;11:582348. doi:10.3389/fphar.2020.582348. PMID: 33132915; PMCID: PMC7578422.

10. Çap M, Bilge O, Işık F, et al. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019. J Electrocardiol. 2020;63:115-119. doi:10.1016/j.jelectrocard.2020.10.015. PMID: 33181454; PMCID: PMC7647409.

11. Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905. PMID: 32929996.

12. El-Sherif N, Turitto G. Torsade de pointes. Curr Opin Cardiol. 2003;18(1):6-13. doi:10.1097/00001573-200301000-00002. PMID: 12496496.

13. Woosley RL, Romero K, Heise CW, et al. Adverse drug event causality analysis (ADECA): a process for evaluating evidence and assigning drugs to risk categories for sudden death. Drug Saf. 2017;40(6):465-474. doi:10.1007/s40264-017-0519-0. PMID: 28275963.

14. Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. Med Clin North Am. 2001;85(2):321-341. doi:10.1016/s0025-7125(05)70318-7. PMID: 11233951.

15. Itoh H, Crotti L, Aiba T, et al. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J. 2016;37(18):1456-1464. doi:10.1093/eurheartj/ehv695. PMID: 26715165; PMCID: PMC4914885.

16. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353-370.

17. Changal K, Paternite D, Mack S, et al. Coronavirus disease 2019 (COVID-19) and QTc prolongation. BMC Cardiovasc Disord. 2021;21(1):158. doi:10.1186/s12872-021-01963-1. PMID: 33784966; PMCID: PMC8007653.

18. Bräuninger H, Stoffers B, Fitzek ADE, et al. Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart [published online October 14, 2021]. Cardiovasc Res. 2021;cvab322. doi:10.1093/cvr/cvab322. PMID: 34647998.

19. Rubin GA, Desai AD, Chai Z, et al. Cardiac corrected QT interval changes among patients treated for COVID-19 infection during the early phase of the pandemic. JAMA Netw Open. 2021;4(4):e216842. doi:10.1001/jamanetworkopen.2021.6842. PMID: 33890991; PMCID: PMC8065381.